Pallas Capital Advisors LLC Acquires 396 Shares of Natera, Inc. (NASDAQ:NTRA)

Pallas Capital Advisors LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 6.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 6,865 shares of the medical research company’s stock after purchasing an additional 396 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Natera were worth $1,087,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new stake in shares of Natera during the second quarter worth $28,000. Quarry LP increased its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd lifted its holdings in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the transaction, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roelof Botha sold 87,473 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the sale, the director now directly owns 1,224,787 shares of the company’s stock, valued at $207,135,977.44. This represents a 6.67 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 123,409 shares of company stock worth $20,045,631. Company insiders own 7.60% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $169.30 on Tuesday. The company has a market cap of $22.35 billion, a P/E ratio of -96.19 and a beta of 1.65. The firm’s fifty day moving average price is $160.14 and its two-hundred day moving average price is $132.44. Natera, Inc. has a one year low of $59.80 and a one year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.95) EPS. Equities analysts expect that Natera, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. TD Cowen boosted their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners increased their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. The Goldman Sachs Group lifted their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Robert W. Baird lifted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.